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Multiscale Modelling of Cancer Response to Oncolytic Viral Therapy
Talal Alzahrani, Raluca Eftimie, Dumitru Trucu∗
Division of Mathematics, University of Dundee, Dundee, DD1 4HN
Abstract
Oncolytic viruses (OV) are viruses that can replicate selectively within cancer cells and destroy them. While the past
few decades have seen significant progress related to the use of these viruses in clinical contexts, the success of oncolytic
therapies is dampened by the complex spatial tumour-OV interactions. In this work, we present a novel multiscale
moving boundary modelling for the tumour-OV interactions, which is based on coupled systems of partial differential
equations both at macro-scale (tissue-scale) and at micro-scale (cell-scale) that are connected through a double feedback
link. At the macro-scale, we account for the coupled dynamics of uninfected cancer cells, OV-infected cancer cells,
extracellular matrix (ECM) and oncolytic viruses. At the same time, at the micro scale, we focus on essential dynamics
of urokinase plasminogen activator (uPA) system which is one of the important proteolytic systems responsible for
the degradation of the ECM, with notable influence in cancer invasion. While sourced by the cancer cells that arrive
during their macro-dynamics within the outer proliferating rim of the tumour, the uPA micro-dynamics is crucial in
determining the movement of the macro-scale tumour boundary (both in terms of direction and displacement magnitude).
In this investigation, we consider three scenarios for the macro-scale tumour-OV interactions. While assuming the usual
context of reaction-diffusion-taxis coupled PDEs, the three macro-dynamics scenarios gradually explore the influence
of the ECM taxis over the tumour - OV interaction, in the form of haptotaxis of both uninfected and infected cells
populations as well as the indirect ECM taxis for the oncolytic virus. Finally, the complex tumour-OV interactions is
investigated numerically through the development a new multiscale moving boundary computational framework. While
further investigation is needed to validate the findings of our modelling, for the parameter regimes that we considered,
our numerical simulations indicate that the viral therapy leads to control and decrease of the overall cancer expansion
and in certain cases this can result even in the elimination of the tumour.
Keywords: multiscale modelling, cancer modelling, tumour – oncolytic virus interactions
1. Introduction
Oncolytic virotherapy (based on either naturally-
occurring or genetically-engineered viruses) is a promising
therapeutic approach for cancer treatment [1]. However,
despite the fact that multiple oncolytic viruses are cur-
rently under clinical development [1], this type of therapy
still has some limitations in terms of efficacy (as observed
in various clinical trials) [2]. This relatively modest on-
colytic efficacy is not only the result of premature virus
clearance due to circulating antibodies and various im-
mune cells [3], but also the result of physical barriers in-
side tumours (e.g., interstitial fluid pressure, extracellular
matrix (ECM) deposits, or tight inter-cellular junctions)
[4, 5]. To improve the intra-tumoural spread of oncolytic
viruses, different experimental and clinical approaches are
currently being considered: from modifications of the im-
mune response to favour virus replication and tumour lysis
[5], to modifications of the physical barriers (e.g., via ECM
degradation) to improve virus spread [6].
∗Corresponding author
Email address: trucu@maths.dundee.ac.uk (Dumitru Trucu)
In this study we consider a mathematical modelling and
computational approach to help us improve our under-
standing of the physical barriers that limit virus spread.
The use of mathematical models to understand the tem-
poral and spatio-temporal dynamics of viruses (including
oncolytic viruses) has seen great developments over the
last three decades [7, 8, 9, 10, 11, 12, 13]. While the ma-
jority of these models focused on the temporal dynamics of
oncolytic viruses (mainly due to the availability of tempo-
ral data) [14, 15, 16, 17, 18, 19, 20, 21, 22, 23], more recent
advances in tumour imaging generated data on the spatial
spread of tumours and viruses, which then led to the de-
velopment of different mathematical models investigating
the spatial spread of these viruses [21, 23, 24, 25, 26, 27].
All these temporal and spatio-temporal models for on-
colytic virus therapies usually focus on one single spatial
or temporal scale. In this context potential insights from
the wide range of singe-scale spatio-temporal modelling
approaches for cancer invasion (such as those proposed in
[28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40] and, in
particular, those involving the theory of mixtures
proposed in [41, 42, 43]) become increasingly relevant
to this area, as highlighted and explored by a number
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of recent works [44, 45, 46, 47]. Nevertheless, since the
process of cancer development is a complex phenomenon
that involves interlinked phenomena that occur at different
scales, it is important to capture these multiscale aspects
also during the tumour-oncolytic virus interactions. To
that end, the multiscale modelling of cancer invasion intro-
duced over the past decade in the mathematical literature
[48, 49, 50, 51, 52] paved the way for exploring the tumour-
OV interaction in a multiscale fashion. However, to our
knowledge, there are not many multi-scale mathematical
models for the oncolytic viral therapies and tumour-viral
interactions, with [53] being the only reference that we
could find in the literature.
In this paper we will introduce a novel multiscale mod-
elling framework for the tumour-OV interaction in which
the macroscopic (tissue-scale) dynamics of the cancer and
oncolytic virus densities will be connected via a double
feedback loop to the microscopic (cell-scale) proteolytic
dynamics of the urokinase plasminogen activator system
(uPA) that takes place at the invasive edge of the tumour.
2. Multiscale Hypothesis and Settings: the Novel
Two-Scale Moving Boundary Modelling Ap-
proach for tumour-OV interactions
Building on the two-scale moving boundary framework
introduced first by Trucu et al. in [51] and later explored
in [52] in the context of the uPA System, in this work
we address the genuinely multiscale nature of tumour-OV
interaction through a new multiscale modelling approach.
Specifically, the tissue-scale (macro-scale) in tumour-OV
interaction is here coupled with the cell-scale (micro-scale)
tumour invasive edge molecular dynamics of the uPA Sys-
tem. Therefore, before exploring further their crucial
cross-talk, we distinguish here the two levels of dynamics,
namely macro-scale and micro-scale, which at this stage
can be generally described mathematically as follows.
On one hand, at macro-scale, at any spatio-temporal
macro-node (x, t), a part of the cancer cells population
c(x, t) becomes dynamically infected by an incoming on-
colytic virus v(x, t), giving rise to an infected cancer cells
population i(x, t), causing these to die, and this way to be
eliminated from the total tumour mass (c+i)(x, t). As this
interaction does occur in the presence of the surrounding
ECM density u(x, t) and, per unit time, this is governed
by both random motility and by various forms of taxis
of both uninfected and infected as well as of the oncoly-
otic virus towards ECM gradients. Thus, denoting for the
moment with T the resulting 4D-reaction-diffusion-taxis
differential operator of order 2, we obtain that the macro-
dynamics can be written as
T (c, i, u, v)T = 0 (1)
were T will be specified in detail in the next section.
On the other hand, at micro-scale, the proteolytic activ-
ity of the uPA System occurring at the invasive edge of the
tumour exercises a cross-tumour boundary local enzymatic
transport within a cell-scale neighborhood of the interface
of the expanding tumour Ω(t), crucially contributing to-
wards its dynamics changes in morphology with respect to
time. Therefore, at any spatio-temporal micro-node (y, τ),
considering the three components of the uPA System,
namely the urokinase plasminogen activator (uPA) a(y, τ),
plasminogen activator inhibitor (PAI-1) p(y, τ) and plas-
min m(y, τ), per unit time their dynamics is driven by
random molecular motility as well as their production and
natural decay. Therefore, we can express this in the form
of a coupled system of reaction diffusion equations. Hence,
similar to the macro-scale, denoting here the resulting 3D-
reaction-diffusion operator by Z, the micro-dynamics can
therefore be expressed as
Z(a, p,m)T = 0 (2)
where the form of the differential operator Z will be made
explicit in the next section.
Following a similar two scale approach as in [51, 52],
within a maximal tissue-scale region Y , the macro-scale
tumour-OV dynamics (1) occurring on the growing tumour
support Ω(t) ⊂ Y is directly linked through a “macro-
micro cross-talk” to the uPA micro-dynamics (2) that
takes place on a cell-scale neighbourhood of the tumour
boundary ∂Ω(t), as illustrated in schematic Fig. 1. To
that end, the cell-scale neighbourhood of ∂Ω(t) that was
introduced in [51] and is given by a covering bundle of
overlapping (half-way) micro-domains {εY }
εY∈P(t) enables
the decoupling of the micro-dynamics in a bundle of micro-
processes taking place on each εY ∈ P(t), and as a con-
sequence, this macro-micro cross-talk is realised through
a double-feedback loop consisting of both top-down and
bottom-up links between the macro-dynamics on Ω(t) and
the uPA micro-dynamics occuring on each εY ∈ P(t).
While we postpone the detailed description of the dou-
ble feedback loop until the next section, briefly, this is
structured as follows.
On one hand, the top-down link between macro-scale
and micro-scale explores the naturally arising source for
the uPA and the non-local behaviour of PAI-1 removal,
which are enabled by the cancer cells and ECM micro-
environment within the neighbourhood of the tumour
outer proliferating rim that secrets them. Thus, on a time
perspective [t0, t0 + ∆t] this arises as the direct contribu-
tion of the macroscopic densities of cancer cells c and i as
well as of the ECM u, and in brief, at any spatio-temporal
microscopic node (τ, y) ∈ [0,∆t]× εY , these can be math-
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where λ is the Lebesgue measure on R2 and the mappings
R 3z 7−→K1(·, ·, z)∈R and R3z 7−→K2(·, z)∈R are com-
pactly supported radially symmetric kernels that quantify
the contribution of the involved macroscopic densities with
respect to their spatial distribution and whose choice will
be discussed in Section 4. In the presence of these non-
local behaviours induce from the macro-scale, the uPA
System exercise its spatio-temporal micro-dynamics briefly
outlined above and detailed in Section 4.
Finally, the bottom up link is conveyed by the key
contribution that the micro-dynamics has in determining
the characteristics of macro-scale tumour boundary move-
ment. The tumour boundary relocation is caused by the
local invasion of the peritumoural region whose extent and
orientation are dictated by the pattern of degradation of
the ECM by the uPA System acting at micro-scale within
the outer part of the cell-scale neighbourhood of the tu-
mour boundary (which is given here by the union of all
the micro-domains εY ∈ P(t)). In its turn, the pattern
of ECM degradation is dictated by the regions of signifi-
cant transport of proteolytic enzymes within each micro-
domain εY . Proceeding as in [51], these regions are de-
termined here by the furthest away part of the level sets
of significant proteolytic enzymes within each εY with re-
spect to the tumour boundary ∂Ω(t)∩ εY , whose cumula-
tive revolving orientation leads to the establishment of the
characteristics of the tumour boundary movement
s : ∂Ω(t)→ S1 × (0,∞),
given by
s(z) := (ν(z), ξ(z)), ∀z ∈ ∂Ω(t),
(5)
with S1 being the usual unit sphere in R2, and ν(·) and ξ(·)
representing the direction of movement and displacement
magnitude, respectively. Provided that sufficient degrada-
tion but not complete destruction of the ECM has been
exercised by the micro-scale uPA processes, the boundary
will be relocated in the direction dictated by the bound-
ary movement law s(·) introduced above, and the macro-
dynamics is continued on the newly obtained domain.
3. Macroscopic Modelling Scenarios for the Virus-
Tumour Interaction
In the following we describe in detail the various macro-
scale components and their dynamics relations, which were
compactly represented by the macroscopic operator equa-
tion (1) introduced in the previous section. These compo-
nents are: the density of uninfected cancer cells c(x, t), the
density of infected cancer cells i(x, t), the density of the ex-
tracellular matrix u(x, t), and the density of the oncolytic
virus particles v(x, t).
Uninfected Cancer Cells: c(x, t). We assume that the
cancer cells density changes due to random cell move-
ment (with Dc the random motility coefficient) and to
Figure 1: Schematic of the multiscale modelling approach to
tumour-virus interaction
directed haptotactic movement towards higher ECM gra-
dients (with ηc the haptotactic coefficient). Moreover, can-
cer cells can proliferate logistically at a rate µ1 [54, 55],
and can decay due to virus infection at a rate ρ. These
assumptions can be translated into the following equation:
∂c
∂t
= Dc∆c− ηc∇ · (c∇u) + µ1c(1− c)− ρcv. (6)
Infected Cancer Cells: i(x, t). We assume that also the
infected cancer cells can move randomly (with Di the ran-
dom motility coefficient). As discussed above, these cells
are infected at a rate ρ by the oncolytic virus. Finally,
these infected cells die at a rate δi. These assumptions are
described by the following equation:
∂i
∂t
= Di∆i+ ρcv − δii. (7)
Extracellular Matrix (ECM): u(x, t). We assume that the
ECM (and its components) does not move, and thus we
ignore any migration and diffusion terms. However, since
ECM is continuously remodelled by cells in the environ-
ment [56], we describe this remodelling process as the dif-
ference between a logistic growth term (describing the de-
position of ECM components – in the presence of cancer –
at a rate µ2) and a degradation term (with αc the rate of
ECM degradation by uninfected cancer cells, and αi the
rate of ECM degradation by infected cancer cells.) These
assumptions are described by the following equation:
∂u
∂t
= −u(αcc+ αii) + µ2u(1− u− c− i). (8)
The growth in equation (8) describes the logistic
remodelling of the ECM, which depends on the
presence of all variables in the system. Similar
terms have been considered in [36, 39, 40, 51, 52].
In contrast, the growth in equation (6) models can-
cer proliferation in the presence of nutrients and
its slow down when nutrients are consumed, as jus-
tified by the shape of the logistic term [54, 55].
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Oncolytic Virus: v(x, t). Assume that the oncolytic virus
can move randomly through the environment, with Dv
the random motility coefficient. The level of virus parti-
cles increases due to the burst (at a rate b) of the infected
tumour cells, which release the new virions in the environ-
ment. The reduction in the number of free virus particles
is the result of the natural virions’ death rate δv, and the
trapping of these virus particles into the cancer cells at
a rate ρ. Therefore, the evolution of the density of virus
particles is described by the equation
∂v
∂t
= Dv∆v + bi− ρcv − δvv. (9)
Remark. Note that for simplicity, in the above
equations (6)-(8), all variables have been rescaled
by their maximum values (i.e., the carrying capac-
ities of the tumour cells and the extracellular ma-
trix).
Therefore, accounting for at the above macro-scale mod-
elling considerations, the macro-dynamics that we have
obtained so far is as follows:
Macro-dynamics scenario 1. The new macro-scale sce-
nario of the multiscale modelling approach for the tumour-
OV interaction is given by the following system:
∂c
∂t = Dc∆c− ηc∇ · (c∇u) + µ1c(1− c)− ρcv,
∂i
∂t = Di∆i+ ρcv − δii,
∂u
∂t = −u(αcc+ αii) + µ2u(1− u− c− i),
∂v
∂t = Dv∆v + bi− ρcv − δvv.
(10)
However, expanding now the modelling perspective by
accounting within the macro-scale spatial dynamics of the
infected cell population not on only on its random move-
ment (approximated here by diffusion) but also on its hap-




= Di∆i− ηi∇ · (i∇u) + ρcv − δii. (11)
This leads us to a second scenario for the macro-dynamics
which is summarised as follows:
Macro-dynamics scenario 2. In the presence of haptotac-
tic behaviour for the infected cell population, the macro-
scale modelling scenario for tumour-OV interaction is
therefore extended and is given now by the system:
∂c
∂t = Dc∆c− ηc∇ · (c∇u) + µ1c(1− c)− ρcv,
∂i
∂t = Di∆i− ηi∇ · (i∇u) + ρcv − δii,
∂u
∂t = −u(αcc+ αii) + µ2u(1− u− c− i),
∂v
∂t = Dv∆v + bi− ρcv − δvv.
(12)
Finally, we note that a major obstacle that creates diffi-
culties in having a successful viral therapy is virus motility
blockage exercised by ECM components. Recent efforts to
minimising virus size makes it possible for the virus parti-
cles to move through ECM components [4]. While knowing
that though viruses do not have an autonomous motility,
the penetration of the ECM is done via other factors, such
as matrix degrading enzymes as detailed in [57]. There-
fore, for the dynamics of the virus population, in addition
to the usual consideration of virus diffusion, assumed by
other authors [23, 25, 26, 21, 4], we will also consider here
the ECM-OV interactions. To that end, as discussed in [4],
while ECM acts usually as a barrier agains OV motility,
its regions of lower levels of density provide opportunities
for OV to penetrate through its components and poten-
tially interact with a larger cancer cell-surface cumulated
areas, this way gaining further opportunities to infect the
nearby cancer cells. This leads to an ECM-OV taxis
behaviour that affects the random motility of the
virus, which mathematically can be incorporated




= Dv∆v − ηv∇ · (v∇u) + bi− ρcv − δvv, (13)
where ηv is the ECM-OV-taxis rate. This brings us to the
last and most extended macro-dynamics scenario that we
consider in this paper, namely:
Macro-dynamics scenario 3. Accounting also upon the
presence of ECM-OV taxis behaviour included in (13), the
macro-dynamics component of our multiscale approach to
tumour-OV interaction is therefore given by:
∂c
∂t = Dc∆c− ηc∇ · (c∇u) + µ1c(1− c)− ρcv,
∂i
∂t = Di∆i−ηi∇ · (i∇u) + ρcv − δii,
∂u
∂t = −u(αcc+ αii) + µ2u(1− u− c− i),
∂v
∂t = Dv∆v − ηv∇ · (v∇u) + bi− ρcv − δvv.
(14)
Remark. Note that since the focus of the model
is the interaction between virus and cancer cells
in a multi-scale moving boundary context, for sim-
plicity we assume that the outside environment is
represented only by the ECM. Therefore, we ig-
nore any other types of cells in the environment:
healthy cells, immune cells, etc.
4. The Microscopic Proteolytic Dynamics and the
Macro-Micro Double Feedback Loop
As briefly outlined in Section 2, both uninfected and in-
fected tumour cells arriving during their dynamics within
the outer proliferating rim of the tumour are able to secrete
uPA. Thus, at any time instance t0, within any micro-
domain εY ∈ P(t0), a source of uPA arises this way at
any micro-point y ∈ εY ∩ Ω(t0) as a collective contribu-
tion of both infected and uninfected cells from the outer
proliferating rim that arrive within a δ > 0 distance from
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y. Therefore, assuming, no spatial discrimination between
the cells secreting the uPA within B(y, δ)∩Ω(t0) , we ob-
tain that the spatially radial symmetric diffusion kernel
K1 appearing in (3) is constant with respect to the spatial
variable, this being given by
K1(c(·, ·), i(·, ·), z) = [λcc(·, ·) + λii(·, ·)]χB(y,δ)∩Ω(t0)(·).
(15)
where χB(y,δ)∩Ω(t0)(·) is the usual characteristic function
for the set B(y, δ) ∩Ω(t0). Thus, we have that the micro-
scale uPA source at a spatio-temporal micro-node (y, τ) ∈







(λcc(s, t0 + τ) + λii(s, t0 + τ))ds
λ(B(y, δ) ∩ supp{c+i})
(16)
and is zero at any other micro location y ∈ εY \Ω(t0). Once
secreted, the uPA exercises a local cross-interface trans-
port process, activating plasmin from its inactive state,
plasminogen, which is freely available within the ECM. In
turn, once activated, plasmin degrades various ECM com-
ponents.
However, the plasminogen activation process is accom-
panied also by inhibitors, a notably important one be-
ing PAI-1, who binds to the activated uPA and manage
to inhibit this. Produced through the activation of plas-
min, besides natural decay and binding to uPA, PAI-1 is
removed also through binding to the surrounding ECM.
Thus, proceeding similar to the case of uPA source, at
each spatio-temporal micro-node (y, τ) ∈ εY × [0,∆t] this
loss of PAI-1 through indiscriminate ECM binding can be
quantified through (4), for the following projection kernel
K2 that is constant with respect to space, namely











Thus, denoting the micro-scale densities of uPA by a(y, τ),
PAI-1 by p(y, τ), and plasmin by m(y, t), and proceeding
as in [58], in brief, the dynamics of the tumour invasive
edge proteolytic micro-processes can be is described as fol-
lows. Per unit time, the uPA molecular population a(·, ·)
changes through diffusion (with a random motility coeffi-
cient Da) while being produced (at a rate ψ12) and bound
by cancer cells’ uPA receptors (uPAR) (at a rate ψ13), as
well as being inhibited by PAI-1 density p(·, ·) (at a rate
ψ11). Therefore, its dynamics is given by
∂a
∂τ
= Da∆h1︸ ︷︷ ︸
diffusion











Further, the inhibitor PAI-1 density change per unit time
is triggered by local diffusion (with a diffusion coefficient
Dp), production through plasmin activation (at a rate ψ23)
as well as removal from the system through binding to uPA
(at a rate ψ21) and to surrounding ECM (at a rate ψ22).
Thus, PAI-1 micro-dynamics is given by
∂p
∂τ
= Dp∆p︸ ︷︷ ︸
diffusion





(y, τ)︸ ︷︷ ︸
PAI-1/ECM




Finally, the change in plasmin density per unit time is
due to local diffusion (with a diffusion coefficient Dm),
natural degradation (at a rate ψ33) and production due to
both direct plasminogen activation (through uPA binding
to uPAR at a rate ψ31) and as well as binding of PAI-
1 to neighbouring ECM (at a rate ψ32) that indirectly
enable further opportunities for plasmin activation. Thus,
plasmin’s micro-dynamics is given by
∂m
∂τ
















As introduced and detailed in [51], on each boundary
micro-domain εY , it is the pattern of significant ECM
degradation (caused by the advancing distribution of plas-
min) that will dictate the relocation of the tumour bound-
ary within the peritumoural region. Indeed, the micro-
scale proteolytic dynamics determines directly the direc-
tion of movement and displacement magnitude that is
briefly summarised in (5) and is represented back at the





, as detailed in [51, 52]. However,
the boundary point x∗
εY
∈ εY will exercise the movement
prescribed by s(x∗
εY
) provided that the extent of degra-
dation of ECM, which is explored here through the outer













, λ(G) > 0,
0, otherwise,
(22)
is significant but not complete. Therefore, the represen-




q∗(εY ) > ω(εY, β) (23)
where ω(εY, β) is a local tissue threshold and the parame-
ter β ∈ (0, 1) explore the optimal conditions for movement,
see Appendix B. Once the movement has been exercised,
the macro-scale tumour domain Ω(t0) progresses to its new
shape Ω(t0 + ∆t), where the multiscale dynamics is con-




Figure 2: Initial Conditions: (a) uninfected cancer cells den-
sity; (b) ECM density; (c) OV density (one initial dose) and
(d) OV density (five initial doses). The white line indicates
the boundary of the total tumour cells (uninfected & infected
densities).
5. Multiscale Numerical Simulation and Results
The computational approach developed in this work ex-
tends the multiscale numerical framework first introduced
in [51] and later applied in [52]. The novel computa-
tional part of this study is the incorporation of the
viral component into the macroscale part of the
multiscale framework presented in [51]. This com-
bines a finite difference approach at macro-scale with a fi-
nite element method at micro-scale. While the finite differ-
ence approach at macro-scale involves central differences
and midpoint approximations (as detailed in Appendix C),
the finite element at micro-scale involves bilinear shape
functions on a square mesh on each εY .
In brief, we consider that the macro-scale dynamics of
the progressing tumour Ω(t) takes place within a maximal
tissue domain Y = [0, 8]×[0, 8], which we discretise by uni-
formly spatial mesh of a size ∆x = ∆y = h = 0.03125. We
used a second order midpoint rule for approximating the
diffusion and haptotactic terms (for both cancer cells) in
all macro-dynamics modelling scenarios (10),(12),(14), as
well as for the ECM-OV taxis term in (14), and we proceed
with a trapezoidal predictor-corrector for time marching
at macro-scale in all cases. The implicit trapezoidal
corrector ensures the stability of the macroscopic







(τ, y) (appearing within the top-down macro-micro
link) contributing towards the sources and removal terms
within the uPA System micro-dynamics (19)-(21) are cal-
culated using direct formulas at overlapping macro-micro
spatial nodes and via interpolation involving barycentric
coordinates at all other off-macro grid micro-spatial points
y ∈ εY . Finally, in the presence of these terms induced
from the macroscale, the micro-dynamics is solved via fi-
nite element with bilinear shape functions on a square
mesh with trapezoidal corrector for time marching. The
direction and displacement magnitude obtained in each
boundary micro-domain εY ∈ P(t0) in conjunction with
the extent of ECM degradation determine the movement
of the tumour boundary at macro-scale, which is recorded
on the macro-scale uniform grid where the dynamics is
then continued for the next time interval [t0 +∆t, t0 +2∆t]
with the next macro-micro stage. This numerical ap-
proach was implemented by ourselves, as detailed
in [51].
5.1. Macro-Dynamics Initial Conditions.
The multiscale dynamics is started with the following
initial conditions on Y for each of the three macro-scale
scenarios, namely:












where θ1(x) := χB((4,4),0.5−γ) ∗ ψγ , with the molifiler
ψγ enabling a smooth transition to zero after 0.5 ra-
dius, as shown Fig. 2(a).
• infected cancer initial conditions:
i(x, 0) = 0.
• extracellular matrix initial conditions:
u(x, 0) =
1 + 0.3sin(4π ‖x‖2) + sin(4π ‖(4, 0)− x‖2)
2
as shown in Fig. 2(b);











where θ2(x) := χB((4.5,4.5),0.5−γ)∗ψγ , as shown in Fig.
2(c).
However, to explore the impact of multiple virus doses, for
the results in Figure 10, we use the initial condition with
five doses of oncolytic virus that is shown in Figure 2(d)





















where we have that θi,j(x) := χB((4+0.5i,4+0.5j),0.5−γ) ∗ψγ ,
∀i, j ∈{−1, 1}.
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Figure 3: Multi-scale simulation results for macro-dynamics scenario (10) at four macro-micro stages (1,50,100, and 150) for the
baseline parameter values from Table A.1, showing: a. virus density; b. infected cancer cells density; c. uninfected cancer cells
density; (d) total cancer cells density; and e. ECM density.
Remark. The specific initial conditions for
the oncolytic virus were chosen to simulate the
effect of injecting the virus particles inside the
tumour or at tumour boundary. Such approaches
are often considered in experimental settings
[59, 60].
5.2. Multiscale numerical results for the three macro-scale
scenarios
In this section, we investigate numerically the three
macroscale scenarios introduced previously. We aim to
observe the cancer response to oncolytic viral therapy via
tracking the macro-micro model behaviour on the maximal
tissue domain Y with respect to several aspects such as:
cancer cells density, cancer boundary expansion, or cancer
suppression.
For the numerical investigation of these three macroscale
scenarios (10), (12), and (14), we first choose a list of base-
line parameters (mainly based on the published studies in
[26, 52]), and investigate the outcome of the assumptions
incorporated in these three cases. Second, we investigate
the effect of changing some of the parameters involved in
virus dynamics and spread: the death rate of infected can-
cer cells (δi), the viral infection rate (ρ), the ECM degra-
dation rates by uninfected cancer cells (αc) and infected
cancer cells (αi), the virus replication rate (b), and the
initial administered virus dose. Finally, based on the out-
come of these results with different parameter values, we
discuss the conditions that lead to improved tumour sup-
pression.
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Figure 4: Multi-scale simulation results for macro-dynamics scenario (12) at four macro-micro stages (1,50,100, and 150) for the
baseline parameter values from Table A.1, showing: a. virus density; b. infected cancer cells density; c. uninfected cancer cells
density; d. total cancer cells density; and e. ECM density.
Baseline Results. The following simulation results are ob-
tained with the baseline parameter values listed in Ta-
bles A.1 (for the macroscopic component) and A.3 (for the
microscopic component). In all figures shown below, the
white curve represents the boundary of the total tumour
(i.e., uninfected and infected cells) within the maximal tis-
sue domain Y .
In Figures 3, 4 and 5 we present the multiscale simula-
tions for the coupled dynamics of uninfected cancer cells
(sub-panels c.), OV-infected cancer cells (row b.), extracel-
lular matrix (ECM) (row e.) and oncolytic viruses (row a.),
for the three macro-dynamics scenarios described by (10),
(12) and (14), respectively. We also show (row d.) the total
cancer cell density (i.e., uninfected plus infected cells). For
all simulations, we start with the uninfected cancer cells
density as shown in Figure2(a), and the virus density as
shown in Figure 2(c) (where the virus is initially located on
the tumour edge ∂Ω(t), namely at (x, y) = (4.5, 4.5)). The
columns show the macroscopic evolution of the tumour-
ECM-virus system at four different stages of the macro-
micro interactions: stages 1, 50, 100 and 150.
We observe that in the absence of haptotatic migration
against ECM gradients for both infected cells and viruses
(as described by macro-dynamics scenario (10)), the virus
infects mainly the areas of the tumour with lower cell den-
sities (see stage 150 in Figures 3a. and 3c.)
If we consider haptotactic migration of virus-infected
tumour cells against the ECM gradients (as described by
macro-dynamics scenario (12)), we observe a large reduc-
tion in tumour size where the virus is located (see stage
150 in Figures 4a. and 4c.).
Finally, if we consider the haptotactic migration of both
8






Figure 5: Multi-scale simulation results for macro-dynamics scenario (14) at four macro-micro stages (1,50,100, and 150) for the
baseline parameter values from Table A.1, showing: a. virus density; b. infected cancer cells density; c. uninfected cancer cells
density; d. total cancer cells density; and e. ECM density.
virus-infected cells and virus particles towards ECM gra-
dients (as described by macro-dynamics scenario (14)), we
observe an even better reduction in tumour size which is
the result of a better virus spread throughout the tumour
(see stage 150 in Figures 5a. and 5c.).
The baseline tumour mass evolution across all macro-
micro stages (1–150) for macro-dynamics scenarios (12)
and (14) are shown in Figure 12 with blue dotted lines and
compared agains five relevant cases of parameter variation,
as detailed in the next paragraphs.
In the following, we focus on the last two macro-
dynamics scenarios, (12) and (14), and investigate the
effect of changes in various model parameters related to
virus dynamics and spread (parameters which can be var-
ied experimentally to impact virus kinetics [61]). For con-
ciseness, Figures 6-10 below will show the results obtained
only at macro-micro stages 75 and 150 of the multiscale
dynamics.
Infected Cells’ Death Rate. We start our investigation into
the effects of different model parameters on treatment out-
comes, by focusing first on the rate δi at which the infected
cells are eliminated from the system (by the anti-viral im-
mune response [62]). As mentioned before, we discuss the
impact of this rate on macro-dynamics scenarios (12) and
(14). In panels Ia. and IIa. of Figure 6 we reduce δi by
a factor of four (i.e., to δi/4), and we observe that the
uninfected tumour cells are reduced dramatically in those
areas occupied also by the oncolytic virus. This result
makes sense, since the persistence of infected tumour cells
gives rise to more virus particles replicating inside these
cells. On the other hand, increasing δi by a factor of four
(i.e., to 4δi) leads to a poorer elimination of tumour cells,
as observed in panels Ib. and IIb. of Figure 6. However,
9












Figure 6: Multi-scale simulation results for macro-dynamics scenarios (12) (in panel I) and (14) (in panel II), showing two variations
of the baseline infected cancer cells death rate δi (namely: a.
δi
4
; and b. 4δi) at macro-micro stages: 1. stage 75; and 2. stage 150.
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Figure 7: Multi-scale simulation results for macro-dynamics scenarios (12) (in panel I) and (14) (in panel II), showing two variations
of the baseline viral infection rate ρ (namely: a. ρ
5
; and b. 5ρ) at macro-micro stages: 1. stage 75; and 2. stage 150.
11







Figure 8: Multi-scale simulation results for ECM degradation rates αc = 0.3 and αi = 0.15 for macro-dynamics scenarios(12) (in
panel I) and (14) (in panel II) at two macro-micro stages: a. stage 75; and b. stage 150.
as shown inFigure 12(1), beyond the overall tumour mass
being kept under control, δi alone does not bring a clear
influence towards suppressing the tumour, as tumour re-
lapses to levels above the baseline occur both when we
lower and when we increase the cell death rate.
Infection Rate of Tumour Cells. In the following, we ex-
amine the effect of viral infection rate (ρ) on tumour dy-
namics. Experimental studies have shown that increasing
the rate at which the oncolytic virus infects the tumour
cells (e.g., by engineering the virus particles to encode
specific proteins that could temporarily suppress anti-viral
immune responses) plays a key role in the development of
new anti-cancer therapies [61]. To investigate this aspect,
we performed various simulation tests for the macroscopic
models (12) and (14), as we decreased and increased the
baseline value ρ = 79 × 10−3 by a factor of five (to ρ5
and 5ρ, respectively). From panels Ia. and IIa. of Fig-
ure 7, we observe that a five-fold decrease in the infection
rate ρ leads to a much faster spread of the tumour cells
(as described by the expanding tumour boundary), com-
pared to the case where the infection rate is increased five
fold - as shown in panels Ib. and IIb. of Figure 7. As
shown in Figure 12(2)(II) with green dotted line, the five
fold increase in ρ leads to significantly better global tu-
mour suppression with respect to the baseline or five fold
decreased cases within the macro-dynamics scenario (14).
A similar although weaker tumour suppression effect ob-
served for macro-dynamics scenario (12), where a relapse
occurs over the final stages of the time interval, as shown
by Figure 12(2)(I).
ECM Degradation Rates. Known to be crucial within the
process of cancer cells’ invasion of the surrounding tissue
[63, 64], the ECM is expected to play also an important
role in viral therapy. Indeed, the ECM distribution within
the growing tumour Ω(t) interfere with the oncolytic virus
dynamics, having impeding effects upon its spread, re-
stricting the viral duplication, and lowering the effective-
ness of cytolytic. However, the degradation for the ECM
provides opportunities for potentially raising the effective-
ness of OV treatments by facilitating a less demanding
virus passage within the tumour tissue, gaining an eas-
ier access to uninfected cancer cells sites [46]. Thus, the
success or failure of the oncolytic virus distribution will de-
pend on the ECM degradation, and this is confirmed also
by our results obtained by doubling the degradation rate
(with respect to the baseline) and shown in panels Ia.–b.
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Figure 9: Multi-scale simulation results for macro-dynamics scenarios (12) (in panel I) and (14) (in panel II), showing two variations
of baseline OV replication rate b (namely: a. b = 0; and b. b = 3) at macro-micro stages: 1. stage 75; and 2. stage 150.
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and IIa.–b. of Figure 8 for the macro-dynamics (12) and
(14), respectively.
As illustrated in Figure 8 an increase in degradation
rate causes not only changes in the morphology of the
growing tumour, but also a decay in the tumour mass,
as reflected in Figure 12(3). This decay in the total tu-
mour mass for the macro-dynamics scenario (12) is the ef-
fect of the following interacting dynamics. The increased
ECM degradation causes both infected cancer and unin-
fected cancer cells to bias their migration haptotacticly
towards the emerging regions of elevated ECM levels, en-
abling this way a local congregation of the two cancer cell
subpopulations (infected and uninfected), which mediates
in its turn a higher degree of infection spread among the
uninfected cancer cells, resulting this way in a decrease
in tumour mass. However, as by comparing panels Ia.–b.
with IIa.–b. in Figure 8, the total cell population exhibits
slightly limited spread with no pronounced fingering in
the macro-dynamics scenario (14) as opposed to macro-
dynamics scenario (12) where the tumour develops large
fingering growth. This particular behaviour within macro-
dynamics (14) is due to the biased migration of both the
infected and uninfected cancer cells as well as of the on-
colytic virus against ECM gradients, this enabling them
to congregate within the same regions, leading this way to
increased levels of local tumour decay.
Viruses Replication Rate. Another factor that impacts
virus kinetics is its replication rate (i.e., the number of
virus particles release by an infected tumour cell) [61]. It
is expected that an increase in the virus replication rate
will lead to a decrease in the tumour size. We confirm this
through the results shown in panels Ib.1.–2. and IIb.1.–2.
of Figure 9 for macro-dynamics scenarios (12) and (14),
respectively, where we considered a higher virus replica-
tion rate (namely b = 3) than the corresponding baseline
value (from Table A.1) used in Figures 4 and 5. This over-
all tumour decrease is also confirmed by the tumour mass
estimate, represented in Figure 12 (4) through the green
dotted line, which shows that, at all macro-micro stages
(1-150), the tumour mass for the increased virus replica-
tion rate b is below the corresponding baseline scenario.
Finally, the absence of viral replication (i.e., b = 0),
explored here through our multiscale approach in panels
Ia.1.–2. and IIa.1.–2. of Figure 9 for macro-dynamics sce-
narios (12) and (14), leads to an increase in spatial spread
of the tumour, giving rise to pronounced fingering and
elongated tumour infiltrations in the surrounding tissue.
Moreover, Figure 12 (4) shows that the tumour mass in
the absence of virus replication (in red dotted line) stays
above the baseline results and continues to increase at all
macro-micro stages (1-150).
Viruses Doses. Acknowledging the therapeutic impor-
tance of virus dosage [65] and accounting in this regard
on a series of biological constraints reviewed in [4], the
virus doses should be balanced in size and, for a more effi-
cient viral therapy, these need to be higher than the initial
tumour size [16]. Moreover, the location of the virus doses
is important for the spatio-temporal viral dynamics within
the growing tumour Ω(t) [66], as their distribution in the
immediate proximity of high density tumour regions have
the potential of a faster viral infection and spread within
Ω(t). These biological observations are explored also by
our results in Figure 10, where we investigate the effect
of spatial distribution of initial viral dosage by increas-
ing their number to 5 identical doses that were spatially
applied as shown by Figure 2(d). As indicated also in
Figure 12(5), after an initial rapid decrease over the first
30 stages (not shown also in Figure 10), the tumour dis-
tribution recovers and exhibits a more compact growth.
This leaves the virus dosage question open and raise the
challenging problem of designing a more comprehensive
strategy where new virus doses need to be applied in ap-
propriate locations at later stages so that tumour control
and elimination could be achieved.
Improved Viral Therapy Outline for Tumour Suppression.
Building on the tumour–OV interraction scenarios and
their associated numerical results explored in Figures 4
– 10, an improved therapy is obtained by cumulating and
using the parameter values identified there to give better
tumour control and suppression response. Summarised in
Table A.2, the changes in the parameters (with respect to
their baseline values) considered in this improved therapy
outline include: a four time decrease of the virus replica-
tion rate, a five fold increase in the infection rate of tu-
mour cells, doubled ECM degradation rate, 50% increase
in virus replication rate. Thus, in the presence of the five
initial virus doses given in Figure 2(d), the results obtained
via these outlined parameter changes, shown in Figure 11,
present significant improvements in the tumour suppres-
sion results for macro-dynamics scenarios (12) and (14),
both in terms of tumour levels and in spatial spread. The
level of uninfected cells drops dramatically and the overall
tumour remain fairly compact, presenting only a limited
growth over the spatial domain, throughout the entire ob-
servation period. The tumour mass evolution plotted there
with red dotted line in Figure 12(6) shows a complete con-
trol of the tumour which, besides a local-in-time relapse,
is brought to residual total mass levels in both macro-
dynamics scenarios (12) and (14), over the 150 macro-
micro stages. Furthermore, by exploring this improved
outline for the tumour – OV interaction on a longer time
perspective of 350 macro-micro stages, as shown in Figure
13(I) we obtain the a good long term control of the tu-
mour, this presenting a limited spatial growth (figure not
shown here) and its overall mass being brought to residual
levels in both macro-dynamics scenarios (12) and (14).
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Figure 10: Multi-scale simulation results for five virus initial doses for macro-dynamics scenarios (12) (in panel I) and (14) (in
panel II) at two macro-micro stages: a. stage 75; and b. stage 150.
6. Conclusions and Discussions
In this paper we proposed a novel multi-scale moving
boundary framework to describe the complex interactions
between the tissue-scale (macro-scale) cancer cells (unin-
fected and infected) populations, ECM, oncolytic virus, in
the presence of the cell-scale tumour invasive edge uPA
microdynamics. The macro-dynamic of tumour–oncolytic
virus interaction give rise to the source for the leading
uPA micro-dynamics via a nonlocal operator, this way es-
tablishing a top-down link between tissue- and cell- scale
levels of activity of this naturally multiscale process.
In the presence of the source induced from the macro-
scale, the uPA exercises a cross-interface micro-transport
on a cell-scale neighbourhood of the tumour boundary
∂Ω(t) that is given by the union of a bundle of “half-way”
overlapping micro-domains {εY }εY ∈P(t). This bundle of
“half-way” overlapping micro-domains enabled the decou-
pling of the micro-dynamics in terms of the dynamics on
each micro-domain εY ∈ P(t). On each micro-domain εY ,
the significant levels of proteolytic transport in the peri-
tumoural regions enabled us the determine the patterns of
significant degradation of the ECM that the uPA meets
and interacts with on εY \ Ω(t). The spatial distribution
of this significant level of proteolytic enzymes enable us to
characterise the choreographic direction of movement and
displacement magnitude of the interface ∂Ω(t) ∩ εY and
to represented this back at macro-scale in the form of a
macro-scale tumour boundary velocity. This macro-scale
tumour boundary velocity determined at micro-scale es-
tablishes a bottom-up feedback that is crucial in decipher-
ing the morphological evolution of the macro-scale tumour.
At macro-scale we considered a cascade of three scenar-
ios for tumour–OV interaction, summarised in (10),(12)
and (14), in which taxis towards ECM gradients is gradu-
ally introduced for uninfected cancer cells, infected cancer
cells, and oncolytic virus, respectively.
Indeed, per unit time, the first macro-scale scenario
given in (10) accounts for the random motility of the unin-
fected cells, uninfected cells and virus particle within the
surrounding ECM in the presence of the usual processes of
virus infection, virus replication, ECM degradation, unin-
fected cell-proliferation and infected cell death, while con-
sidering taxis against ECM gradients (haptotaxis) only for
the uninfected cell population. The modelling context is
then extended to the macro-dynamics scenario (12) when
haptotaxis is also considered for the infected cell popula-
tion, and finally this is completed with macro-scale sce-
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Figure 11: Multi-scale simulation results for the improved outline for tumour suppression for macro-dynamics scenarios (12) (in
panel I) and (14) (in panel II) at two macro-micro stages: a. stage 75; and b. stage 150.
nario (14) when also the implicit ECM taxis movement of
the virus is accounted for in the form of an ECM-OV taxis
term.
As an initially considered baseline parameter values set
(given in Table A.1) for all three macro-dynamics scenar-
ios ((10), (12) and (14)) did not ensure an effective tu-
mour suppression (as seen in Figures 3–5), we explored fur-
ther the tumour–OV interaction conditions for the macro-
dynamics scenarios (12) and (14) by varying the infected
cancer cells death rate, the viral infection speed, the ECM
degradation rates, viral replication rate, as well as the spa-
tial distribution of initial virus doses. In doing so, we
identified not only successful therapeutical cases, but also
situations where the oncolytic viral therapy failed to lead
to tumour suppression. As reflected by Figure 12, the fail-
ure of viral threatment could be clearly identified in two
cases, namely: (1) slowing down viral infection speed (as
shown in panels Ia.1.–2. and IIa.1.–2. of Fig.7 and Fig-
ure 12(2)); and (2) the absence of viral replication induced
by infected cancer cells (as shown in panels Ia.1.–2. and
II)a.1.–2. of Figure 9 and Figure 12(4)). Whether facing
a slowdown of the infection rate or being in the absence of
viral replication, the uninfected tumour cells gain momen-
tum and become the dominant player, proliferating and
driving the spatial invasion, enhancing the overall tumour
mass and giving rise to pronounced fingering patterns.
However, improved tumour suppression scenarios were
found for the following parameter changes with respect to
their baseline vales, namely for: (a) reducing the infected
cell death rate (shown in Figure 6); (b) increased viral in-
fection rate (shown in Figure 7); (c) increased ECM degra-
dation rate (shown in Figure 8); (d) increased viral replica-
tion rate (shown in Figure 9). Alongside these parameter
changes, a spatial redistribution of initial virus dosage in
the proximity of tumour was found to have benefic impact
upon tumour mass control and spatial spread.
Finally, a combination of best parameters that we found
for tumour suppression led to an even better control of
the tumour mass and tumour spatial spread as shown in
Figures 11 and 12(6) Here the distribution of uninfected
cancer cells is kept for most time observed at very low lev-
els and the spatial spread is compact and very limited for
both macro-dynamics scenarios considered, (12) and (14).
An even longer observation of time, showed here in Figure
13 revealed that despite two instances of tumour relapses
(captured by the only two peaks in tumour masses Figure
13 ) the tumour growth is suppressed and the tumour itself





Figure 12: Comparison of total tumour masses evolution over macro-micro stages 1 – 150 between the macro-dynamics scenarios
(12) (in subfigures (I)) and (14) (in subfigures (II)) for the following cases of parameter variations with respect to their baseline
values given in Table A.1, namely: (1) (a) δi
4
, (b) baseline value for δi, and (c) 4δi; (2) (a)
ρ
5
, (b) baseline value for ρ, and (c) 5ρ;
(3) (a) 2αc,2αi, and (b) baseline values for αc and αi; (4) (a) no OV replication, b = 0, (b) baseline value for b, and (c) b=3; (5)
(a) five OV initial doses and (b) one OV initial dose; (6) (a) parameter for improved viral therapy outline for tumour suppression
given in Table A.3, and (b) baseline parameter values given in Table A.1.
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Figure 13: A long run (350 macro-micro stages) of the improved
outline for tumour suppression case . (I) A comparison of total
tumour masses between macro-dynamics modelling scenarios:
(a) (14) and (b) (12). (II) A comparison of viruses masses
between macro-dynamics modelling scenarios: (c) (14) and (d)
(12).
quite similar overall tumour mass dynamics, which
is expected since the difference between scenarios
(12) and (14) is in the advection of virus and does
not affect the total tumour mass (because the rates
at which the virus kills the tumour are the same for
the two scenarios). Thus, while tumour control could be
in principle achieved, a complete tumour elimination that
would not present relapses opens the challenging question
of designing a optimal strategy for iterative delivery of new
tumour doses at appropriate spatial locations, this being
the topic of a future work.
Appendix A. Summary of Model Parameters
Appendix A.1. Summary of baseline parameter values that
appear in the macro-dynamics scenarios
In Table A.1, we summarise the baseline parameter
values for the most complex macro-dynamics model (14)
(these parameters appear also in models (10) and (12)).
The majority of these parameter values are taken from
two references, [26] and [52].
Appendix A.2. Parameter values for macro-dynamics sce-
nario showing the best tumour suppression
results, as summarised in Figures 11 and
12
In Table A.2, we summarise the values of parameters ρ,
δi, αc, αi and b (for the macro-dynamics scenarios,(12) and
(14)), that have shown to lead to best tumour suppression
results.
Appendix A.3. Summary of baseline parameter values that
appear in the micro-dynamics scenarios






ηc 2.85× 10−2 [52]
ηi 2.85× 10−2 [52]
ηv 2.85× 10−3 Estimated
µ1 0.25 [52]












Table A.1: Baseline parameters values for the macroscopic mod-
els (10), (12) and (14). The last three parameters, β, λc and λi




















Table A.2: Summary of parameter values that have shown im-
proved tumour suppression results, as summarised in Figures
11 and 12.
Appendix B. Tissue Thresholds within the
bottom-up feedback link
As discussed in [51], for each εY ∈ P(t0), the tissue
thresholds ω(β, εY ) explore the level of ECM degradation
on εY \Ω(t0), this way assessing the likelihood of movement
of the midpoint x∗εY to the new location prescribed by




















Table A.3: Summary of parameter values for the microscopic
modelling component. All parameters for this system are taken
from the reference [52].
thresholds are given by
ω(β, εY ) =














where β ∈ (0, 1) represents the most suitable conditions
that facilitate invasion, with the expressions Q1(β, εY ) and
Q2(β, εY ) denoting



















Appendix C. Outline of the Numerical Approach
Appendix C.1. Spatial Domain Discretization
• We assume that the tumour Ω(t) grows within a maxi-
mal reference spacial domain Y , which is taken in our
numerical experiments to be the rectangular region
Y := [0, 8] × [0, 8]. Details of the macro-solver are
given in the next appendix subsection.
• We discretise Y uniformly in both spatial directions
with a equal mesh size ∆x = 0.03125.
• Micro Domain and Details of the Micro-Solver :
1. For any time instance t0 ≥ 0, any boundary
micro-domain εY ∈ P(t0) is centred a bound-
ary point x ∈ ∂Ω(t0) ∩ εY , having its size ε =
2∆x = 0.0625.
2. The top-down nonlocal source terms ... we using
the directly the formulas (16) and (18) the over-
lapping macro-micro mesh points and use micro-
scale barycentric coordinates to interpolate at all
other micro-points y ∈ εY \ {(i∆x, j∆x) | i, j =
1...q}.
3. On each εY we then solve the micro-dynamics
via finite element by involving bilinear shape
function on a square micro-mesh placed on εY .
Appendix C.2. Macro-Solver
• The macro-dynamics is solved over the time interval
[t0, t0+∆t], which is uniformly discretised inN+1 > 1
time nodes with equal size time step δ̂t := ∆tN . This
is approximated via method of lines type approach
with a trapezoidal predictor-corrector time marching
approach.
• For the approximation of the right-hand side spa-
tial operator, we involve midpoint rule and central
differences, and so, at any discrete spatial point
(i∆x, j∆x), ∀i, j = 1, ..., q, and any given time node
tn := t0 + nδ̂t, ∀n = 0, ..., N , we have that:













the haptotaxis terms are approximated by:































































































via the usual midpoint rule.
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